Halozyme Therapeutics (HALO) Net Cash Flow (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Net Cash Flow of $175.6 million for Q1 2026, up 190.33% year-over-year from $60.5 million in Q1 2025, and up 161.99% quarter-over-quarter from -$283.2 million in Q4 2025.
Halozyme Therapeutics (HALO) Net Cash Flow (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Net Cash Flow for 17 consecutive years, with $175.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 190.33% year-over-year to $175.6 million; the TTM figure through Mar 2026 stood at $135.7 million (up 1059.57% YoY), while the FY2025 annual figure was $20.6 million, up 916.31% from the prior year.
- Net Cash Flow advanced to $175.6 million in Q1 2026 per HALO's latest filing, from -$283.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $357.8 million in Q3 2025 and bottomed at -$283.2 million in Q4 2025.
- Historically, Net Cash Flow has averaged $11.3 million across 5 years, with a median of $23.2 million in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 15489.59% — and 2025, when it jumped 1166.61%.
- Halozyme Therapeutics' Net Cash Flow stood at $87.0 million in 2022, then slumped by 279.07% to -$155.9 million in 2023, then surged by 75.32% to -$38.5 million in 2024, then sank by 636.31% to -$283.2 million in 2025, then surged by 161.99% to $175.6 million in 2026.
- Business Quant data shows HALO's Net Cash Flow at $175.6 million in Q1 2026, -$283.2 million in Q4 2025, and $357.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | -148.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -148.02 Mn |
| Jun 30, 2026 | -148.02 Mn |
| Mar 31, 2026 | 175.59 Mn |
| Mar 31, 2026 | 175.59 Mn |
| Dec 31, 2025 | -283.24 Mn |
| Dec 31, 2025 | -283.24 Mn |
| Sep 30, 2025 | 357.80 Mn |
| Sep 30, 2025 | 357.80 Mn |
| Jun 30, 2025 | -114.47 Mn |
| Jun 30, 2025 | -114.47 Mn |
| Mar 31, 2025 | 60.48 Mn |
| Mar 31, 2025 | 60.48 Mn |
| Dec 31, 2024 | -38.47 Mn |
| Dec 31, 2024 | -38.47 Mn |
| Sep 30, 2024 | -33.55 Mn |
| Sep 30, 2024 | -33.55 Mn |
| Jun 30, 2024 | 23.24 Mn |
| Jun 30, 2024 | 23.24 Mn |
| Mar 31, 2024 | 46.26 Mn |
| Mar 31, 2024 | 46.26 Mn |